# THE USE OF BUPRENORPHINE/NALTREXONE COMBINATION TREATMENT IN ATTENUATING RELAPSE TO MORPHINE/METHAMPHETAMINE POLYDRUG-DEPENDENCE IN MICE

BY

#### MARYAM SAADAH BINTI SUHAIMI

A thesis submitted in fulfilment of the requirement for the degree of Master in Pharmaceutical Sciences (Pharmacology)

Kulliyyah of Pharmacy International Islamic University Malaysia

FEBRUARY 2017

#### **ABSTRACT**

Currently, there is an increasing pattern of methamphetamine abuse among opioid users and yet there is no pharmacological treatment approved by Food and Drug Administration (FDA) to treat methamphetamine dependence. Since kappa-opioid receptor has been associated with relapse to many drugs of abuse, this receptor might have the potential to prevent relapse to both methamphetamine and opioid. Therefore, this study aims to investigate the involvement of the kappa-opioid receptor system in relapse related to morphine/methamphetamine (polydrug) addiction. Firstly, naltrexone was assessed in a tail-withdrawal test to ensure its ability in suppressing the mu-opioid receptor activity of buprenorphine in mice at 52 °C warm water bath. The tailwithdrawal test was also used to identify the minimum dose of methamphetamine that can produce analysic effects in order to determine the dose responsible in activating the mu-opioid receptor. Both of these assays were crucial since this study aims to investigate the involvement of kappa-opioid receptor rather than the rest of opioid receptor (e.g. mu-opioid receptor) in preventing drug relapse. Next, conditioned place preference (CPP) test was used to investigate the ability of the treatment candidates (buprenorphine/naltrexone combination and norbinaltorphimine, nor-BNI) in drug relapse model in mice. Method validation and optimisation for the CPP test were conducted prior to the test to ensure that the conditioning and priming dose, confinement time as well as time interval applied in the test are optimum. Then, the CPP test was conducted to compare the ability of these two treatment regimes in morphine-. reinstatement methamphetaminemorphine/methamphetamine polydrug-dependence. Based on the result, 1.0 mg/kg naltrexone pretreatment successfully block the mu-opioid receptor agonist activity of 0.3 mg/kg buprenorphine by showing a decrease in tail-withdrawal latency in the tail-withdrawal test. This proved that the combination of buprenorphine/naltrexone treatment is able to mask the mu-opioid receptor agonism of buprenorphine and act as a functional kappa-opioid antagonist. Moreover, it was found that the minimum dose of methamphetamine that can produce analgesic effect in the tail-withdrawal test is at 5.0 mg/kg. Hence, 1.0 mg/kg methamphetamine used in the CPP test will have no effect on the mu-opioid receptor and any dependence induced at this dose is not related to the mu-opioid receptors activity. In the CPP test, the combination of 0.3 mg/kg buprenorphine and 1.0 mg/kg naltrexone pretreatment (ip) was able to attenuate morphine- (7.5 mg/kg, ip) and morphine/methamphetamine (7.5 mg/kg and 1.0 mg/kg, ip respectively) polydrug-reinstatement but not methamphetamine-reinstatement (1.0 mg/kg, ip). However, pretreatment with 10.0 mg/kg norbinaltorphimine (a selective kappa-opioid attenuated morphine-reinstatement antagonist) only methamphetaminemorphine/methamphetamine polydrug-reinstatement. and Therefore, it can be suggested that methamphetamine and morphine/methamphetamine polydrug-dependence may involve other important receptors and neurocircuit besides the kappa-opioid receptor. Further studies on immunohistochemistry autoradiography may be crucial to rule out the involvement of kappa-opioid receptor in mediating relapse to morphine-, methamphetamine- or morphine/methamphetamine polydrug-dependence.

#### خلاصة البحث

هناك حاليا نمط متزايد من حالات تعاطى الميتامفيتامين بين مستخدمي الأفيونات، ولا يوجد حتى الآن علاج دوائي موافق على من قبل إدارة الغذاء والدواء الأمريكية (FDA) لعلاج ادمان الميتامفيتامين .ارتبطت مستقبلات كابا الأفيونية مع حالات الانتكاس في العديد من انواع تعاطى المخدرات، وقد يكون لدى هذا المستقبل القدرة على منع حالة الانتكاس في إدمان الميثامفيتامين والأفيونات. لذلك هدفت هذه الدراسة إلى التعرف على دور نظام مستقبلات كابا الأفيونية في حالات الانتكاس المتعلقة بإدمان المورفين والميثامفيتامين (تناول عقاقير متعددة). أولا، تم تقييم النالتريكسون في اختبار سحب الذيل للتيقن من قدرتما في قمع نشاط مستقبلات ميو-أفيون من البوبرينورفين في الفئران عند 52 درجة مئوية. تم استخدام اختبار سحب الذيل أيضا لتحديد الحد الأدبى لجرعة المخدر التي يمكن أن ينتج عنها التأثيرات المسكنة من أجل تحديد الجرعة المسؤولة في تفعيل مستقبلات ميو -أفيون. هذه الاختبارات كانت مهمة جدا لأن هذه الدراسة هدفت إلى التحقيق في تورط مستقبلات كابا الأفيونية وليس غيرها من المستقبلات الأفيونية (مثل مستقبلات ميو-أفيون) في الوقاية من حالات الانتكاس. بعد ذلك، تم استخدام اختبار تفضيل المكان المهيأ (CPP) للتحقيق في قدرة المعالجين (مزيج البوبرينورفين والنالتريكسون والنوربينالتورفيمين، والغير BNI) في غوذج انتكاس المخدرات في الفئران. تم إجراء اختبارات التحقق وتحسين الأداء لاختبار الـ CPP قبل الاختبار الرسمي للتأكد من التكييف، والجرعات المناسبة، أوقات الحبس، وكذلك الفترات الزمنية التي طبقت في الاختبار هي الأمثل .ثم، وأجري اختبار اله CPP لمقارنة قدرة المعالجين في معاملة اثنين في تخفيف العودة للمورفين، والميثامفيتامين ومزيج المورفين والميثامفيتامين .استنادا إلى النتائج، 1.0 ملغم / كغم من المعالجة المسبقة بالنالتريكسون كتلة بنجاح نشاط مستقبلات ناهض مو الأفيونية من 0.3 ملغم / كغم البوبرينورفين من خلال إظهار انخفاض في الكمون ذيل الانسحاب في اختبار الذيل الانسحاب . أثبت هذا أن الجمع بين العلاج البوبرينورفين / النالتريكسون قادر على حجب مستقبلات التحولي مو الأفيونية من البوبرينورفين ويكون بمثابة خصم كابا الأفيونية وظيفية .وعلاوة على ذلك، فقد وجد أن أقل جرعة من مخدر التي يمكن أن تنتج تأثير مسكن في اختبار الذيل الانسحاب هي عند 5.0 ملغم /كغم .وبالتالي، 1.0ملغم /كغم من الميثامفيتامين المستخدمة في الاختبار CPP لن يكون لها أي تأثير على مستقبلات مو الأفيونية وأي الاعتماد الناجم عند هذه الجرعة لا علاقة للنشاط مستقبلات كابا الأفيونية . في الاختبار حزب الشعب الكمبودي، فإن الجمع بين 0.3 ملغم / كغم البوبرينورفين و 1.0 ملغم / كغم من النالتريكسون المعالجة (الملكية الفكرية) قادرة على تخفيف المورفين (7.5 ملغ / كغ، والملكية الفكرية) والمورفين / الميثامفيتامين (7.5 ملغ / كغ و 1.0 ملغ / كغ، والملكية الفكرية على التوالي) تناول عقاقير متعددة، ولكن ليس إعادة الميتامفيتامين إعادة (1.0 ملغ / كغ، والملكية الفكرية .(ومع ذلك، فإن المعالجة مع 10.0 ملغ / كغ ولا-أخطار الحريق (انتقائي كابا الأفيونية خصم) الموهن فقط المورفين إعادة ولكن المورفين / الميثامفيتامين تناول عقاقير متعددة-إعادة .ولذلك، فإنه يمكن أن يكون اقترح ان الميثامفيتامين والمورفين / الميثامفيتامين تناول عقاقير متعددة الاعتماد قد تنطوي على مستقبلات أخرى مهمة الدوائر العصبية بالإضافة إلى مستقبلات كابا الأفيونية .قد يكون إجراء المزيد من الدراسات على المناعية وتصوير الإشعاع الذاتي حاسم لاستبعاد تورط مستقبلات كابا الأفيونية في التوسط الانتكاس إلى أو المورفين / الميثامفيتامين تناول عقاقير متعددة الاعتماد.

#### APPROVAL PAGE

I certify that I have supervised and read this study and that in my opinion, it confort to acceptable standards of scholarly presentation and is fully adequate, in scope a quality, as a thesis for the degree of Master in Pharmaceutical Science (Pharmacolog	
	Irna Elina Ridzwan Supervisor
	Abdul Razak Kasmuri Co-Supervisor
I certify that I have read this study and that in standards of scholarly presentation and is fully ad for the degree of Master in Pharmaceutical Scient	equate, in scope and quality, as a thesis
	Syed Zahir Idid Syed Osman Idid Internal Examiner
	Sharif Mahsufi Mansor External Examiner
This thesis was submitted to the Department of last a fulfilment of the requirement for the degree (Pharmacology).	
	Nurul Asyiqin Yusof Head, Department of Basic Medical Science
This thesis was submitted to the Kulliyyah of Ph of the requirement for the degree of Master in Ph	· •
	Juliana Md. Jaffri Dean, Kulliyyah of Pharmacy

#### **DECLARATION**

I hereby declare that this thesis is the result of my own in	vestigations, except where
otherwise stated. I also declare that it has not been previously	or concurrently submitted
as a whole for any other degrees at IIUM or other institution	s.
Maryam Saadah Binti Suhaimi	
Signature	Date

#### INTERNATIONAL ISLAMIC UNIVERSITY MALAYSIA

### DECLARATION OF COPYRIGHT AND AFFIRMATION OF FAIR USE OF UNPUBLISHED RESEARCH

## THE USE OF BUPRENORPHINE/NALTREXONE COMBINATION TREATMENT IN ATTENUATING RELAPSE TO MORPHINE/METHAMPHETAMINE POLYDRUG-DEPENDENCE IN MICE

I declare that the copyright holder of this thesis are jointly owned by the student and IIUM.

Copyright ©2017 Maryam Saadah Binti Suhaimi and International Islamic University Malaysia. All rights reserved.

No part of this unpublished research may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, recording or otherwise without prior written permission of the copyright holder except as provided below.

- 1. Any material contained in or derived from this unpublished research may be used by others in their writing with due acknowledgement.
- 2. IIUM or its library will have the right to make and transmit copies (print or electronic) for institutional and academic purposes.
- 3. The IIUM library will have the right to make, store in a retrieval system and supply copies of this unpublished research if requested by other universities and research libraries.

By signing this form, I acknowledged that I have read and understand the IIUM Intellectual Property Right and Commercialization policy.

Affirmed by Maryam Saadah Binti Suhaimi	
Signature	 Date

#### **ACKNOWLEDGEMENTS**

"In the name of Allah, the Most Compassionate, the Most Merciful. Praise be to Allah, Lord of the universe, and peace and prayers be upon His final Prophet and Messenger"

Alhamdulillahi rabbil 'alamin. Above all, I remain thankful to Allah Subhanahu wa ta'ala in the accomplishment of this research and thesis. I would like to express my deepest appreciation to all those who provided me the possibility to complete this work.

Firstly, it is my utmost pleasure to dedicate this work to my dear parents, Meriam Ishak and Suhaimi Sudin, and my beloved family, Muhammad Syafiq, Nur Izni, Maryam Sakinah, Maryam Syuhada, Maryam Syamilah and Sharifah Nurul Hidayah, who granted me the gift of their unwavering belief in my ability to accomplish this goal: thank you for your support and patience.

A special gratitude I gave to my supervisor, Asst. Prof. Dr. Irna Elina Ridzwan and my co-supervisor, Assoc. Prof. Dr. Abdul Razak Kasmuri, whose contribution in stimulating suggestions and encouragement, helped me to coordinate my project in the laboratory and also in writing this thesis. I will be forever grateful and indebted.

I wish to express my appreciation and thanks to those who provided their time, effort and support for this project. I would like to acknowledge with much appreciation, the crucial role of the staff of Kulliyyah of Pharmacy, who gave the permission to use all required equipment and the necessary materials to complete the laboratory experiment. A special thanks to the science officer: Sis Siti Rusianti, and all laboratory technician: Sis Ayu, Sis Sri, Sis Salmi, Bro Adi and Bro Zack. Not to forget, all Postgraduate administrative officer, Sis Haslina, Sis Syuhaiha, Sis Shaheeda and Sis Nurul.

My sincere thanks also goes to my colleagues and laboratory mates: Kak Nur 'Izzati, Kak Nurul Hafizah, Fathin Athirah, Huwaida, Nurlaili Najmie, Hanisuhana, Nurul Adilah, Nur Syafinaz, Bro Fahmi, Bro Solahuddin, and Bro Anugerah. Thanks for the stimulating discussions, for the time we were working together, and for all the fun we had.

Last but not least, thank you very much to all who were directly or indirectly involved in this project. Thanks for the love, care and support. May Allah bless all of you with His mercy and compassion, here and hereafter.

#### TABLE OF CONTENTS

Abstract	ii
Abstract in Arabic	iii
Approval Page	iv
Declaration	v
Copyright Page	vi
Acknowledgements	vii
List of Tables	xi
List of Figures	xii
List of Equations	xiv
List of Abbreviations	XV
CHAPTER ONE: INTRODUCTION	1
1.1 Research Background	1
1.2 Research Problem	4
1.3 Significance of Study	5
1.4 Objectives of Study	6
1.4.1 General Objective:	6
1.4.2 Specific Objectives:	6
1.5 Research Hypothesis	6
CHAPTER TWO: LITERATURE REVIEW	7
2.1 Overview of Drug Addiction	7
2.1.1 Stages of Drug Addiction	8
2.1.2 Reinforcement in Drug Addiction	10
2.2 Neurocircuitry of Drug Addiction	12
2.2.1 Neurocircuitry of Opioids Addiction	17
2.2.2 Psychostimulant Addiction	25
2.2.2.1 Overview of Psychostimulant	25
2.2.2.2 Neurocircuitry of Psychostimulant Addiction	26
2.2.3 Overlapping of Opioids and Psychostimulant Neurocircuits	28
2.2.4 Neuroplasticity as a Factor to Produce Relapse	
2.3 Treatment for Drug Addiction	31
2.3.1 The Combination of Buprenorphine/Naltrexone Treatment	31
2.4 Animal Models of Drug Addiction	34
2.4.1 Conditioned Place Preference (CPP) Test	34
2.4.2 Tail-withdrawal Test	39
CHAPTER THREE: METHODOLOGY	40
3.1 Subjects	40
3.2 Drugs	
3.3 Tail-withdrawal Test	41
3.3.1 Apparatus	41
3.3.2 Procedures	41
3 3 3 Data Analysis	43

3.4 Conditioned Place Preference (CPP) Test	43
3.4.1 Apparatus	
3.4.2 General Procedures	44
3.4.3 CPP Method Validation	
3.4.3.1 Morphine Dose for Conditioning Phase	
3.4.3.2 Morphine Confinement Time for Conditioning Phase	
3.4.3.3 Time Intervals for Morphine and Saline Administration	
during Conditioning Phase	49
3.4.3.4 Morphine-priming for Reinstatement Test	
3.4.4 Data Analysis	
3.5 Straub's Tail Response and Stereotype Behaviour Test	51
3.5.1 Apparatus	
3.5.2 Procedures	51
CHAPTER FOUR: RESULTS AND FINDINGS	54
4.1 Tail-withdrawal Test.	
4.2 Conditioned Place Preference (CPP) Test	
4.2.1 Method Validation	
4.2.1.1 Morphine Dose for Conditioning Phase	
4.2.1.2 Morphine Confinement Time for Conditioning Phase	
4.2.1.3 Time Intervals for Morphine and Saline Administration	
during Conditioning Phase	59
4.2.1.4 Morphine-priming Dose during Reinstatement Test	
4.2.2 CPP Model of Relapse Treatment for Various Drug Dependence	
4.2.2.1 Morphine-conditioned Control Group	62
4.2.2.2 Morphine-conditioned, Buprenorphine/Naltrexone	
(combination) Treated Group	63
4.2.2.3 Morphine-conditioned, nor-BNI Treated Group	
4.2.2.4 Methamphetamine-conditioned Control Group	65
4.2.2.5 Methamphetamine-conditioned, Buprenorphine/Naltrexon	
(combination) Treated Group	
4.2.2.6 Methamphetamine-conditioned, nor-BNI Treated Group	67
4.2.2.7 Morphine/Methamphetamine-conditioned (polydrug)	
Control Group	68
4.2.2.8 Morphine/Methamphetamine-conditioned (polydrug),	
Buprenorphine/Naltrexone (combination) Treated Group.	69
4.2.2.9 Morphine/Methamphetamine-conditioned (polydrug),	
nor-BNI Treated Group	
4.3 Straub's Tail Response and Stereotype Behaviour Test	73
CHAPTER FIVE: DISCUSSION	
5.1 Method Validation and Optimisation	
5.2 Mu-opioid Agonist Activity of Buprenorphine and Methamphetamine	
5.3 Treatment for Relapse in Single and Polydrug Abuse	
5.3.1 Straub's Tail Response and Stereotype Behaviour	

CHAPTER SIX: CONCLUSION	
6.1 Conclusion	91
6.2 Limitation of Study	91
6.3 Future Study	
REFERENCES	94
APPENDIX A: PUBLICATIONS AND PRESENTATIONS	107
APPENDIX B: ANIMAL ETHICS APPROVAL	118

#### LIST OF TABLES

Table No.		Page No
1.1	The Most Commonly Abused Substances	1
2.1	Animal Laboratory Models of the Different Stages of the Drug Addiction Cycle	9
2.2	Neurotransmitters Related to the Drug of Abuse	13
3.1	Stock Solution Preparation	41
3.2	Mice Grouping for the Tail-Withdrawal Test	42
3.3	Number of Mice Used for Each Experiment	45
3.4	Mice Grouping for CPP Test	46
3.5	Grouping for the Straub's Tail Response and Stereotype Behaviour Test	53
4.1	Number of Mice Used and Excluded at Each Phase in CPP Test for Various Morphine Dose	57
4.2	4 Hours Interval for Morphine and Saline Administration	59
4.3	24 Hours Interval for Morphine and Saline Administration	60
4.4	Number of Mice Used and Excluded at Each Phase in CPP Model of Relapse Treatment and Time Taken to Reach Extinction	72
4.5	Results for Straub's Tail Response	73
4.6	Results for Stereotyped Behaviour	74

#### LIST OF FIGURES

Figure No.		Page No
1.1	World Drug Report 2015 for the Year of 2009 - 2013	2
1.2	Drug Abuse Statistics, for the Year of 2010 – 2014	3
2.1	Stages of Drug Addiction	9
2.2	Interrelations Between the Three Main Neurotransmitters Responsible in Drug Addiction and Relapse Processes	13
2.3	Location of the Brain Regions Related to Drug Addiction	14
2.4	Mesocorticolimbic Dopamine System	18
2.5	The Distribution of the Mu-Opioid Receptor	19
2.6	A Schematic Diagram of the Kappa Overdrive Model in Opioid Addiction and Various Treatments to Compensate the Imbalanced Opioid Receptor Activation	22
2.7	Mechanism of Action of Opioids in Brain	24
2.8	Chemical Structure of Psychostimulants Compared to Dopamine	26
2.9	Mechanism of Actions of Methamphetamine in Brain	27
2.10	Mechanism of Action of Cocaine in Brain	28
2.11	A Buprenorphine/Naltrexone Combination Actions Towards the Opioid Receptors	34
2.12	Schematic Drawing of a Two-compartment CPP Box	35
2.13	Schematic Drawing of a Three-compartment CPP Box	35
3.1	Three-Compartment CPP Box	44
3.2	CPP Timeline for General Procedure	45
3.3	CPP Timeline for Method Validation during Conditioning Phase (24 hours interval)	48
3.4	CPP Timeline for Method Validation during Conditioning Phase (4 hours interval)	49

4.1	Tail-Withdrawal Test for 10.0 mg/kg Morphine, 0.3 mg/kg Buprenorphine and 1.0 mg/kg Naltrexone Pretreatment	55
4.2	Tail-Withdrawal Test for 10.0 mg/kg Morphine, Different Dose of Methamphetamine (1.0, 2.0 And 5.0 mg/kg) and 1.0 mg/kg Naltrexone Pretreatment	55
4.3	CPP Test for Different Doses of Morphine to Induce Dependence	57
4.4	CPP Test for Different Morphine Confinement Time During Conditioning Phase	58
4.5	CPP Test for Different Morphine-Priming Doses During Reinstatement Phase	61
4.6	CPP Test for Morphine-Conditioned Control Group	62
4.7	CPP Test for Morphine-Conditioned, Buprenorphine/Naltrexone (Combination) Treated Group	63
4.8	CPP Test for Morphine-Conditioned, Nor-BNI Treated Group	64
4.9	CPP Test for Methamphetamine-Conditioned Control Group	65
4.10	CPP Test for Methamphetamine-Conditioned, Buprenorphine/Naltrexone (Combination) Treated Group	66
4.11	CPP Test for Methamphetamine-Conditioned, Nor-BNI Treated Group	67
4.12	CPP Test for Morphine/Methamphetamine-Conditioned (Polydrug), Control Group	68
4.13	CPP Test for Morphine/Methamphetamine-Conditioned (Polydrug), Buprenorphine/Naltrexone (Combination) Treated Group	70
4.14	CPP Test for Morphine/Methamphetamine-Conditioned (Polydrug), Nor-BNI Treated Group	71
4.15	A Positive Straub's Tail Response	73

#### LIST OF EQUATIONS

Equations No.	<u>.</u>	Page No.
3.1	Increased from baseline (sec) = Post-drug latency – Baseline latency	43
3.2	$Correction \ Factor = Duration \ of \ test \div Total \ time \ in \ A + B$	50
3.3	% Preference = Time in $A \div Duration$ of test $\times$ Correction Factor $\times$ 100 %	50
3.4	% Preference = Time in $B \div D$ uration of test $\times$ Correction Factor $\times$ 100 %	50

#### LIST OF ABBREVIATIONS

°C Celsius

5-HT Serotonin

APA American Psychiatric Association

ATS Amphetamine-Type Stimulants

Bup Buprenorphine

cAMP Cyclic Adenosine Monophosphate

CCTV Closed-Circuit Television

CNS Central Nervous System

CPP Conditioned Place Preference

DA Dopamine

DAT Dopamine Transporter

DSM Diagnostic and Statistical Manual of Mental Disorders

FDA Food and Drug Administration

GABA Gamma-Aminobutyric Acid

GluA1 AMPA-Type Glutamate Receptor

H<sub>2</sub>O Water

HIV Human Immunodeficiency Virus

IACUC Institutional Animal Care and Use Committee

ip Intraperitoneal Injections

KOR Kappa-Opioid Receptor

M3G Morphine-3-Glucuronide

M6G Morphine-6-Glucuronide

MAO-A Monoamine Oxidase A

MDMA 3,4-Methylenedioxy-N-Methyl-Amphetamine (Ecstasy)

Meth Methamphetamine

MMT Methadone Maintenance Treatment

MOR Mu-Opioid Receptor

MPE Maximum Possible Effect

NA Noradrenaline

NAcc Nucleus Accumbens

NADA National Anti-drugs Agency

NIDA National Institute on Drug Abuse

NOP Nociceptin Opioid Peptide

nor-BNI Norbinaltorphimine

Ntx Naltrexone

OF1 Oncins France 1

PFC Prefrontal Cortex

PNS Peripheral Nervous System

PUSPEN Pusat Pemulihan Penagihan Narkotik

sc Subcutaneous

SEM Standard Error Of The Mean

STI Sexually-Transmitted Infections

UNODC United Nations Office on Drugs and Crime

VTA Ventral Tegmental Area

WHO World Health Organization

#### **CHAPTER ONE**

#### INTRODUCTION

#### 1.1 RESEARCH BACKGROUND

Drug addiction is a chronic brain disorder which causes compulsive drug seeking and drug taking behaviour despite the harmful effects (National Institute on Drug Abuse (NIDA), 2014a). In the Diagnostic and Statistical Manual of Mental Disorders (DSM) developed by the American Psychiatric Association (APA), addiction has no specific diagnosis, but can be included in the category of substance use disorder. The symptoms of substance use disorder may include impaired control over individual actions, social impairment, risky use, tolerance and withdrawal (NIDA, 2014a). The most commonly abused substances are depicted in Table 1.1.

Table 1.1 The Most Commonly Abused Substances (NIDA, 2014a)

Drug classification	Examples
Opioids	Morphine and heroin
Psychostimulants	Cocaine, methamphetamine and amphetamine
Cannabis	Marijuana
Hallucinogen	Ecstasy and lysergic acid diethylamide (LSD)
Inhalants	Gasoline and spray paint

In 2013, it was estimated that 3.4 - 7.0 % (162 - 329 million) of the world's population aged 15 - 64 years old had used illicit drugs, with the highest abused drug reported for cannabis (2.7 - 4.9 %), followed by opioids (non-medical use of pharmaceutical opioids like oxycodone) (0.6 - 0.8 %), amphetamines (0.3 - 1.1 %), opiates (heroin and opium) (0.3 - 0.4 %), cocaine (0.3 - 0.4 %) and ecstasy (0.2 - 0.6 %)

(United Nations Office on Drugs and Crime (UNODC), 2015). In the same report, UNODC (2015) also revealed that between 2009 to 2013, cannabis, opiates and opioids were among the highest abused drugs, while amphetamines, ecstasy and cocaine abuse were reducing (Figure 1.1).




Figure 1.1 World Drug Report 2015 for the Year of 2009 - 2013 (UNODC, 2015)

In Malaysia, opioids (heroin and morphine) and methamphetamine are ranked as the most abused drugs from 2010 to 2014 (Figure 1.2) (National Anti-drugs Agency (NADA), 2014). In 2014, NADA reported that 64.8 % (14,496) of total drug addicts were addicted to opioids, followed by methamphetamine (18.4 %), cannabis (8.6 %) and ATS (amphetamine-type stimulants which include ecstasy and amphetamine) (7.9 %). About 37.5 % (8,295) from the total of 22,355 reported cases were relapse related with the highest relapse cases being due to opioids and methamphetamine addiction (78.9 % and 11.2 % respectively) (NADA, 2014).




Figure 1.2 Drug Abuse Statistics, for the Year of 2010 – 2014 (NADA, 2014)

Based on the World Health Organization (WHO) Guidelines (2009), there are two main options for the treatment of opioid addiction. It was either detoxification followed by a long-term maintenance on replacement therapy, or rapid detoxification followed by relapse prevention treatments. As for opioid dependence treatment, there are three main types of medication available which are opioid agonists (oral methadone liquid or sublingual buprenorphine tablets), opioid antagonists (naloxone or naltrexone) and alpha-2 adrenergic agonist (clonidine) (Mclellan, Lewis, Brien, & Kleber, 2000; WHO, 2009). The opioid agonists and antagonists act directly on the mu-opioid receptor (the same receptor that caused opioid dependence), whereas the alpha-2 adrenergic agonist acts by decreasing noradrenaline (NA) activity in the central nervous system (which is increased during withdrawal) (Mclellan et al., 2000; Kirchmayer et al., 2002; Nutt & Lingford-Hughes, 2008). Since most drugs of abuse (such as cocaine, amphetamine, methamphetamine and cannabis) have no approved pharmacological intervention, another possible non-pharmacological treatment is psychosocial intervention (cognitive and behavioural approaches and contingency management

techniques), which has low effectiveness and lacks scientific support (El-Guebaly, Carra, & Galanter, 2015).

#### 1.2 RESEARCH PROBLEM

High relapse incidence (around 55-80 %) were reported among opioid addicts after completed methadone maintenance treatment (MMT) (Tkacz, Severt, Cacciola, & Ruetsch, 2011), making it crucial to revise the current treatment for opioid dependence. Since kappa-opioid receptor is said to be related to relapse of many drugs of abuse (Butelman, Yuferov, & Kreek, 2012), study on the potential treatment to overcome relapse of drug taking should be focused on this receptor. In addition, many drug addicts are addicted to multiple drugs of abuse from different pharmacological classifications, termed as polydrug addiction (Minozzi et al., 2011). There is an increasing pattern of psychostimulants abuse among patients who underwent methadone maintenance treatment (Shaffer & LaSalvia, 1992; Shariatirad, Maarefvand, & Ekhtiari, 2013). Moreover, it was reported that addicts usually take methamphetamine together with morphine to mask the side effects of the drugs (Ito, Mori, Namiki, Suzuki, & Sawaguchi, 2007; Preliminary interview at PUSPEN Gambang, 2013). Thus, not only relapse is a big issue in drug addiction, but polydrug addiction should also be considered as well. Till now, there is no pharmacological treatment approved by Food and Drug Administration (FDA) to treat methamphetamine and polydrug dependence (Pereira & Gough, 2011). Since buprenorphine/naltrexone combination pretreatment showed an ability to attenuate drug-primed reinstatement in cocaine- and morphine-dependent rats (Cordery et al., 2014), it is possible that this drug combination may also possess the ability to attenuate morphine/methamphetamine polydrug dependence as cocaine and methamphetamine are classed in the same pharmacological classification of drug which is psychostimulant, although their neurocircuit might be slightly different. Therefore, this study aims to find the possible drug candidate to treat polydrug addiction related to morphine/methamphetamine and to prevent relapse upon successful detoxification.

#### 1.3 SIGNIFICANCE OF STUDY

The findings of this study will contribute greatly to the benefits of society considering that morphine and methamphetamine are the highest abused drugs for the past 5 years, while polydrug-abuse is becoming popular recently. Treatment that can attenuate relapse of drug taking after successful cessation would be beneficial to ensure effectiveness of the treatment choices. This study aid in developing new treatment option for drug addiction that can enhance the effectiveness of the current treatment and may reduce relapse incidence. It will reveal if opioid receptors can be manipulated to overcome this issue. The researchers can also use the findings as a guide to synthesise a new compound that selectively target the receptors that responsible to cause drug relapse. This study can also be a guide in assessing other possible treatment options related to addiction and relapse. It may provide a clear framework for research in drug addiction field. Therefore, the effectiveness of pharmacological intervention for drug addiction and relapse can be improved.

#### 1.4 OBJECTIVES OF STUDY

#### 1.4.1 General Objective:

To study the involvement of kappa-opioid receptor system in relapse related to morphine/methamphetamine polydrug addiction.

#### 1.4.2 Specific Objectives:

- a) To evaluate the ability of naltrexone to block any mu-opioid receptor agonism of buprenorphine.
- b) To evaluate the ability of buprenorphine/naltrexone combination treatment in attenuating reinstatement to morphine-, methamphetamine- and morphine/methamphetamine polydrug-dependent mice.
- c) To evaluate the independent role of selective kappa-antagonist in attenuating reinstatement to morphine-, methamphetamine- and morphine/methamphetamine polydrug-dependent mice.

#### 1.5 RESEARCH HYPOTHESIS

Antagonism of the kappa-opioid receptor may attenuate reinstatement following morphine-, methamphetamine- and morphine/methamphetamine polydrug withdrawal.

#### **CHAPTER TWO**

#### LITERATURE REVIEW

#### 2.1 OVERVIEW OF DRUG ADDICTION

Drug addiction can be defined as a chronic and relapsing brain disease in which compulsive drug-seeking and drug-use persists despite the serious negative consequences (NIDA, 2014b). According to Le Moal and Koob (2007), the term addiction is previously represented by both physical dependence (discontinuation of prolong drug usage resulting in an intense physical disturbance) and psychological dependence (drug produces rewarding effect and compulsive behaviour that urges regular drug administration, to feel pleasure or avoid discomfort). Currently, it is well accepted that dependence itself means; "A physiological state that can occur with regular drug use and results in withdrawal symptoms when drug use is abruptly discontinued" (NIDA, 2014b). Therefore, addiction and dependence are actually interrelated to one another, and these terms are often interchangeable.

The rate of relapse in drug addiction was similar to other chronic illnesses, such as asthma, hypertension and type I diabetes (NIDA, 2014b), making it important to find the effective treatment for addiction and relapse. Generally, drug addiction affects individual health, mentally (depression and anxiety) and physically (withdrawal symptoms like irritability, insomnia and hot flashes). Furthermore, drug addicts is known to be the major agent for transmitting the infectious diseases such as Human Immunodeficiency Virus (HIV), sexually-transmitted infections (STI), hepatitis, and tuberculosis. Some of these diseases are easily spread through needle sharing which can pose a threat to public health. Other than that, illegal drug use also has a high impact on

socioeconomic status of the country through health care, productivity loss, crime, imprisonment and drug enforcement (Bauer, Soares, & Nielsen, 2015).

#### 2.1.1 Stages of Drug Addiction

Drug addiction developed through a complex interaction of neurobiological components, genetic variables, environmental factors and social aspects (Le Moal & Koob, 2007; Koob & Volkow, 2010; Volkow, Wang, Fowler & Tomasi, 2012). All these factors are also involved in the establishment of drug addiction through the three stages of addiction which occurs in a continuous cycle (Figure 2.1). Drug use begins with either social drug-taking or acute reinforcement, then advances to the escalating or compulsive use, dependence, withdrawal, and usually relapses to the drug-taking; and the cycle continues (Le Moal & Koob, 2007). However, addicts occasionally can stay on recovery stage for a longer time with the help of proper medication and treatment.

The first stage in the addiction cycle (Figure 2.1) is the 'binge/intoxication' stage where drug taking activity gives a positive reinforcement to the addicts, usually named as rewarding effect (e.g. enhance performance and reduce pain). The second stage refers to the 'withdrawal/negative effect' stage where the previous motivating effect (positive reinforcement) of the drug has been shifted towards avoiding the negative effects of the drug withdrawal. The third stage, termed as the 'preoccupation/anticipation' stage is concerned about the drug craving and compulsive drug seeking behaviour (Koob, 2006a).

In order to investigate the causes of repetitive cycle of addiction, different experimental studies can be useful at different stages of addiction. Table 2.1 summarises the appropriate animal laboratory models of the different stages of the drug addiction cycle based on a review by Koob (2009). Current study used conditioned place